Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Operations: 2020-2024

Historic Cash from Operations for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$81.2 million.

  • Taysha Gene Therapies' Cash from Operations fell 11.80% to -$24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.7 million, marking a year-over-year decrease of 7.14%. This contributed to the annual value of -$81.2 million for FY2024, which is 11.24% down from last year.
  • Taysha Gene Therapies' Cash from Operations amounted to -$81.2 million in FY2024, which was down 11.24% from -$73.0 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Cash from Operations ranged from a high of -$30.7 million in FY2020 and a low of -$117.0 million during FY2021.
  • Over the past 3 years, Taysha Gene Therapies' median Cash from Operations value was -$81.2 million (recorded in 2024), while the average stood at -$80.9 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 280.88% in 2021, then increased by 24.48% in 2022.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Cash from Operations stood at -$30.7 million in 2020, then plummeted by 280.88% to -$117.0 million in 2021, then rose by 24.48% to -$88.4 million in 2022, then climbed by 17.39% to -$73.0 million in 2023, then declined by 11.24% to -$81.2 million in 2024.